Innovative drug concept hits bottom and rebounds, Boer Medicine rises more than 10%

Borui Pharmaceuticals rose more than 10%, hitting a new high in over 4 years. Nosiland, Edi Pharmaceuticals, Baiali Tianheng, Rongchang Biotech, Junshi Biotech and others were among the top gainers. According to a research report jointly released by PharmaCube and Tsinghua University, a total of 94 license-out transactions for domestic innovative drugs were completed in 2024, with a total amount of up to 51.9 billion US dollars, an increase of 26% year-on-year.